Vera Therapeutics

CompanyUnited States

Vera Therapeutics develops one asset, in phase 3 (atacicept in berger disease). Mostly protein or enzyme acting on inflammation, TNFSF13 and TNFSF13B; based in the United States.

1
Asset
Furthest: Phase 3; 1
Trial: 0
Signals

Pipeline

1

atacicept
Recombinant fusion protein inhibiting BAFF and APRIL to reduce pathogenic IgA production.
Phase 3, Protein or enzyme, Inflammation, TNFSF13, berger disease, IgA nephropathy

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials1
Similar companies6

Updated 9 Oct 2026 · 3 sources